AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib)
Monday, April 17, 2023
AbbVie announced the European Commission (EC) approved RINVOQ® (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of moderately to severely active crohn's disease.
RINVOQ® (upadacitinib) is the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease having an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Crohn's disease is a burden that can present patients with daily, often uncomfortable challenges. RINVOQ is approved in the EU for the treatment of adults with radiographic axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, adults and adolescents with atopic dermatitis and now Crohn's disease.
The EC approval of RINVOQ in Crohn's disease is a significant milestone in offering patients the first and only once-daily oral treatment that can provide endoscopic improvement, and sustained symptom relief, making a difference in their daily lives. With existing therapies, not all patients are able to achieve adequate disease control to meet their treatment goals, hence IBD portfolio is expanded with new treatment options.
